Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

NK-Cell Leukemia: early-phase trial registry

1 of 2 indexed NK-Cell Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

NK-Cell Leukemia: 2 US clinical trials tracked, 1 recruiting.

NK-Cell Leukemia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is New York Medical College, running 1 of these trials.

Enrollment posture brief

Registry condition nk-cell-leukemia

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%NK-Cell Leukemia (this)50%
Open-enrollment share among volume-matched conditions near NK-Cell Leukemia

NK-Cell Leukemia lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NK-Cell Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NK-Cell Leukemia is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on NK-Cell Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

G-csf Biological
1 trials
Fludarabine Biological
1 trials
pralatraxate, Drug
1 trials
Methotrexate Drug
1 trials
Ifosfamide Drug
1 trials
Thiotepa Drug
1 trials
Dexamethasone Drug
1 trials
Etoposide Drug
1 trials

US sites by state

Facility locations filed on NK-Cell Leukemia trials. A trial with sites in several states counts in each.

Tennessee 1 trials
Ohio 1 trials
New York 1 trials
Michigan 1 trials
California 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NK-Cell Leukemia page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NK-Cell Leukemia condition card totals 2 registered trials; most-linked intervention G-csf; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.